Our September issue review highlights include:
· Antibodies as cancer drugs
· Non-viral gene therapy: spinal cord regeneration
· Global health product development
· Viral targets of acylguanidines
The leading story of this issue of Drug Discovery Today, by Janice M. Reichert and Eugen Dhimolea examines the current commercial clinical pipeline of monoclonal antibodies candidates for cancer. They discuss the trends in the development of antibody–drug conjugates, bispecific antibodies, engineered antibodies and antibody fragments and/or domains.
Click here to view the Drug Discovery Today September issue on ScienceDirect
To register for the Drug Discovery Today Digital Edition click here.